Susquehanna International Group’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-264
Closed -$7.79K 12472
2024
Q4
$7.79K Buy
+264
New +$22.2K ﹤0.01% 11995
2023
Q2
Sell
-532
Closed -$71.3K 12057
2023
Q1
$71.3K Sell
532
-900
-63% -$162K ﹤0.01% 11521
2022
Q4
$591K Buy
1,432
+160
+13% +$66.4K ﹤0.01% 7418
2022
Q3
$490K Buy
1,272
+842
+196% +$276K ﹤0.01% 8545
2022
Q2
$61K Sell
430
-1,076
-71% -$171K ﹤0.01% 11853
2022
Q1
$377K Buy
+1,506
New +$630K ﹤0.01% 9689

Other funds holding BCAB

Susquehanna International Group's BCAB Position: Q1 2026 in Review

Susquehanna International Group reduced its BioAtla (BCAB) stake by 52% in Q1 2026, selling an estimated $9.98K and leaving 781 shares worth $6.29K. The position accounts for ﹤0.01% of the portfolio, ranked #12969.

Susquehanna International Group first reported a position in BCAB in Q2 2021 and has held it in 20 quarters since. The position peaked at $1.88M in Q4 2022. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • Susquehanna International Group held 781 shares of BioAtla worth $6.29K as of Q1 2026.
  • Susquehanna International Group sold 853 BioAtla shares in Q1 2026, an estimated $9.98K.
  • BioAtla made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12969 holding.
  • Susquehanna International Group first reported a position in BioAtla in Q2 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's BioAtla position peaked at $1.88M in Q4 2022.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.